Stanford University - Pharmaceuticals & Healthcare - Deals and Alliances Profile
September 2018
119
About the Report
About the Report
Summary
Stanford University is an educational and research organization that provides graduate and undergraduate programs. The organization's services include education and research facilities. It provides research facilities through its research laboratories and centers. Stanford University includes graduate school of business, school of earth, energy and environmental sciences, graduate school of education, school of engineering, school of humanities and sciences, law school and school of medicine. The organization's academic programs comprise continuing studies, pre-collegiate studies and degrees. It also offers computing and communication infrastructure and support for the teaching, learning and research activities. Stanford University is headquartered in Stanford, California, the US.
Stanford University-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description-A brief description of the company's operations.
- Key Employees-A list of the key executives of the company.
- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors-A list of the key competitors of the company.
- Key Recent Developments-A brief on recent news about the company.
Reasons to buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Products
Products
Stanford University, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.
Table of Contents
Table of Contents
Table of Contents
Table of Contents 3
List of Tables 6
List of Figures 7
Stanford University, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8
Stanford University, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 9
Stanford University, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10
Stanford University, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 11
Stanford University, Medical Devices Deals, 2012 to YTD 2018 12
Stanford University, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 13
Stanford University, Pharmaceuticals & Healthcare, Deal Details 17
Venture Financing 17
Arcus Biosciences Raises USD70 Million in Series B Financing 17
Partnerships 19
Brainsway and Cohen Veterans Bioscience Enter into Research Collaboration Agreement with Stanford University 19
Rocket Pharmaceuticals and Stanford University School of Medicine Enter into Partnership 20
Second Genome Enters into Research Partnership with Stanford Cancer Institute, Ruprecht-Karls University Heidelberg and Roswell Park Cancer Comprehensive Cancer Center 21
Vibliome Therapeutics Enters into Agreement with Stanford University and Montana State University 22
Takeda Pharma Partners with Stanford University 23
Alligator Bioscience Expands Agreement with Stanford University 24
Vedanta Biosciences Enters into Agreement with Stanford University School of Medicine 25
Stanford University's School of Medicine and uBiome Enter into Research Agreement 26
Stallergenes Greer Enters into Agreement with Stanford University 27
Cohen Veterans Bioscience Enters into Agreement with Stanford University School of Medicine 28
RedHill Biopharma Enters into Research Agreement with Stanford University School of Medicine 29
twoXAR Enters into Agreement with Stanford University School of Medicine 30
twoXAR Enters into Research Agreement with Stanford University 31
Intermountain Healthcare Enters into Agreement with Stanford Genome Technology Center 32
SRI Biosciences Enters into Agreement with Stanford Cancer Institute 33
ImmunoCellular Therapeutics Enters into Research Agreement with Stanford University 34
SRI Biosciences Enters into Agreement with Stanford Cancer Institute 35
aTyr Pharma Enters into Agreement with Hong Kong University of Science and Technology, Scripps Research Institute and Stanford University for Human Proteins Discovery 36
Activaero Enters Into Research Agreement With Stanford University 38
Benitec Biopharma Enters Into An Agreement With Stanford University 39
Licensing Agreements 40
Denovo Biopharma Enters into Licensing Agreement with Stanford University 40
Madenco BioSciences Enters into Licensing Agreement with Stanford University 41
Vir Biotechnology Enters into Licensing Agreement with Stanford University 42
Aldevron Enters into Licensing Agreement with Stanford University 43
Stanford University Enters into Licensing Agreement with Trianni for Trianni Mouse 44
Aduro BioTech Enters into Licensing Agreement with Stanford University 45
Neurotrope Enters into Licensing Agreement with Stanford University 46
Renova Therapeutics Enters into Licensing Agreement with Stanford University 47
Mitoconix Bio Enters into Licensing Agreement with Stanford University 48
Abeona Therapeutics Enters into Licensing Agreement with Stanford University 49
Forty Seven Enters into Licensing Agreement with Stanford University 50
Medgenics Enters into Licensing Agreement with Stanford University 51
Eiger BioPharma Enters into Licensing Agreement with Stanford University for Post-Bariatric Surgical Hypoglycemia 52
Eiger BioPharma Enters into Licensing Agreement with Stanford University 53
Eiger BioPharma Enters into Licensing Agreement with Stanford University for Pulmonary Arterial Hypertension 54
Abeona Therapeutics Enters into Licensing Agreement with Stanford University 55
Medicenna Therapeutics Enters into Licensing Agreement with Stanford University 56
Alexo Therapeutics Receives Rights to SIRPA technology from Stanford University School of Medicine 57
Medeor Therapeutics Enters into Licensing Agreement with Stanford University 58
CareDx Amends Licensing Agreement with Stanford University 59
Neurotrope Enters into Licensing Agreement with Stanford University 60
Horizon Discovery Enters into Licensing Agreement with Stanford University 61
Globavir Enters into Licensing Agreement with Stanford University 62
Sitari Pharma Enters into Licensing Agreement with Stanford University 63
Quest PharmaTech Enters Into Licensing Agreement With Stanford University For Anti-MUC1 IgE Technology 64
Personalis Enters Into Licensing Agreement With Stanford University 65
Atreca Enters Into Licensing Agreement With Stanford University For Immune Repertoire Capture Technology 66
Stem Cell Theranostics Enters into Agreement with Stanford University 67
Transparency Life Sciences Enters Into Option Licensing Agreement With Stanford University 68
Acquisition 69
Stanford Health Care Acquires ValleyCare Health 69
Stanford Hospital Acquires CareCounsel Health Advocacy Specialist 70
Stanford University-Key Competitors 71
Stanford University-Key Employees 72
Stanford University-Locations And Subsidiaries 73
Head Office 73
Other Locations & Subsidiaries 73
Recent Developments 74
Legal and Regulatory 74
Mar 05, 2018: Abzena: Settlement of claim 74
Government and Public Interest 75
Aug 08, 2018: Reaching for new stroke treatments by understanding proprioception 75
Aug 06, 2018: Correcting sickle cell-causing mutation with efficient CRISPR-Cas9 genome editing 76
Jul 30, 2018: Study links depression to low blood levels of acetyl-L-carnitine 77
Jul 18, 2018: St. Baldrick's foundation announces USD 19.1 million in grants to fund lifesaving childhood cancer research 79
Jul 18, 2018: Cell membrane's importance offers new strategy to fight infections 80
Jun 12, 2018: More than USD 28 million awarded for new atrial fibrillation research centers to improve patient outcomes 81
Jun 08, 2018: USD 8.1 million grant funds new center to research highly aggressive form of lung cancer 82
May 24, 2018: Clinical Trial Targeting Lung Cancer, Plus Promising Osteoporosis and Incontinence Research get Support from Stem Cell Agency 84
May 23, 2018: Foundation for Anesthesia Education and Research Awards USD 1.4 million in Grants 86
May 02, 2018: Cryo-EM structures of the nicotine receptor may lead to new therapies for nicotine addiction 89
Apr 03, 2018: Stanford scientists combine CRISPR and DNA barcoding to track cancer growth 90
Mar 30, 2018: Stanford researchers use computer simulations to study complexity of concussions 92
Mar 28, 2018: Revolutionary brain-mapping technique provides new blueprint for cortical connections 93
Feb 15, 2018: Breast Cancer Now responds to early research using stem cells to develop 'cancer vaccine' 94
Jan 29, 2018: Kenneth Rainin Foundation: USD 1.7 Million to Improve IBD Patient Outcomes 95
Jan 23, 2018: Damon Runyon Cancer Research Foundation awards USD 3M to eleven innovative early career scientists 96
Dec 14, 2017: Research Targeting Diabetes, Liver Failure and HIV Get Support from California Stem Cell Agency 99
Oct 16, 2017: Scientists uncover a new layer of Complexity Beyond the Human Genome 100
Sep 21, 2017: Pancreatic islets study may spur diabetes treatment advances 101
Sep 20, 2017: Researchers hit the brakes on lethal brain cancers in mice 102
Sep 19, 2017: CPRIT awards USD 34M to UTSW for cancer research recruitment 103
Aug 17, 2017: New Way To Empower The Immune System To Detect And Kill Cancer 105
Product News 106
Jul 17, 2017: Intermountain Healthcare and Stanford University Use Precision Medicine Advances to Understand and Treat Cancer Cases 106
May 01, 2018: Scientist develops protein mimic to help injured lungs breathe 107
Feb 15, 2018: Stem cell vaccine immunizes lab mice against multiple cancers 109
Clinical Trials 110
Nov 20, 2017: Clinical trial suggests new cell therapy for relapsed leukemia patients 110
Other Significant Developments 112
Sep 04, 2018: Tailoring behavioral therapy for depression, obesity based on how the brain responds 112
Aug 15, 2018: Healthcare Innovators professional society reaches member goal of 33 top industry executives for nationwide council 113
Aug 09, 2018: Artificial intelligence model “learns” from patient data to make cancer treatment less toxic 114
Jul 09, 2018: Synthetic surfactant could ease breathing for patients with lung disease and injury 116
Jun 26, 2018: Researchers Explore Stem Cells for Personalized Cancer Vaccines 117
Jun 07, 2018: Blood test may identify pregnant women at risk of premature birth 118
Appendix 119
Methodology 119
About GlobalData 119
Contact Us 119
Disclaimer 119
List of Figure
List of Figures
Stanford University, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Stanford University, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Stanford University, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Stanford University, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Stanford University, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8
Stanford University, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 9
Stanford University, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10
Stanford University, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 11
Stanford University, Medical Devices Deals, 2012 to YTD 2018 12
List of Table
List of Tables
Stanford University, Pharmaceuticals & Healthcare, Key Facts 2
Stanford University, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8
Stanford University, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 9
Stanford University, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10
Stanford University, Deals By Therapy Area, 2012 to YTD 2018 11
Stanford University, Medical Devices Deals, 2012 to YTD 2018 12
Stanford University, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 13
Arcus Biosciences Raises USD70 Million in Series B Financing 17
Brainsway and Cohen Veterans Bioscience Enter into Research Collaboration Agreement with Stanford University 19
Rocket Pharmaceuticals and Stanford University School of Medicine Enter into Partnership 20
Second Genome Enters into Research Partnership with Stanford Cancer Institute, Ruprecht-Karls University Heidelberg and Roswell Park Cancer Comprehensive Cancer Center 21
Vibliome Therapeutics Enters into Agreement with Stanford University and Montana State University 22
Takeda Pharma Partners with Stanford University 23
Alligator Bioscience Expands Agreement with Stanford University 24
Vedanta Biosciences Enters into Agreement with Stanford University School of Medicine 25
Stanford University's School of Medicine and uBiome Enter into Research Agreement 26
Stallergenes Greer Enters into Agreement with Stanford University 27
Cohen Veterans Bioscience Enters into Agreement with Stanford University School of Medicine 28
RedHill Biopharma Enters into Research Agreement with Stanford University School of Medicine 29
twoXAR Enters into Agreement with Stanford University School of Medicine 30
twoXAR Enters into Research Agreement with Stanford University 31
Intermountain Healthcare Enters into Agreement with Stanford Genome Technology Center 32
SRI Biosciences Enters into Agreement with Stanford Cancer Institute 33
ImmunoCellular Therapeutics Enters into Research Agreement with Stanford University 34
SRI Biosciences Enters into Agreement with Stanford Cancer Institute 35
aTyr Pharma Enters into Agreement with Hong Kong University of Science and Technology, Scripps Research Institute and Stanford University for Human Proteins Discovery 36
Activaero Enters Into Research Agreement With Stanford University 38
Benitec Biopharma Enters Into An Agreement With Stanford University 39
Denovo Biopharma Enters into Licensing Agreement with Stanford University 40
Madenco BioSciences Enters into Licensing Agreement with Stanford University 41
Vir Biotechnology Enters into Licensing Agreement with Stanford University 42
Aldevron Enters into Licensing Agreement with Stanford University 43
Stanford University Enters into Licensing Agreement with Trianni for Trianni Mouse 44
Aduro BioTech Enters into Licensing Agreement with Stanford University 45
Neurotrope Enters into Licensing Agreement with Stanford University 46
Renova Therapeutics Enters into Licensing Agreement with Stanford University 47
Mitoconix Bio Enters into Licensing Agreement with Stanford University 48
Abeona Therapeutics Enters into Licensing Agreement with Stanford University 49
Forty Seven Enters into Licensing Agreement with Stanford University 50
Medgenics Enters into Licensing Agreement with Stanford University 51
Eiger BioPharma Enters into Licensing Agreement with Stanford University for Post-Bariatric Surgical Hypoglycemia 52
Eiger BioPharma Enters into Licensing Agreement with Stanford University 53
Eiger BioPharma Enters into Licensing Agreement with Stanford University for Pulmonary Arterial Hypertension 54
Abeona Therapeutics Enters into Licensing Agreement with Stanford University 55
Medicenna Therapeutics Enters into Licensing Agreement with Stanford University 56
Alexo Therapeutics Receives Rights to SIRPA technology from Stanford University School of Medicine 57
Medeor Therapeutics Enters into Licensing Agreement with Stanford University 58
CareDx Amends Licensing Agreement with Stanford University 59
Neurotrope Enters into Licensing Agreement with Stanford University 60
Horizon Discovery Enters into Licensing Agreement with Stanford University 61
Globavir Enters into Licensing Agreement with Stanford University 62
Sitari Pharma Enters into Licensing Agreement with Stanford University 63
Quest PharmaTech Enters Into Licensing Agreement With Stanford University For Anti-MUC1 IgE Technology 64
Personalis Enters Into Licensing Agreement With Stanford University 65
Atreca Enters Into Licensing Agreement With Stanford University For Immune Repertoire Capture Technology 66
Stem Cell Theranostics Enters into Agreement with Stanford University 67
Transparency Life Sciences Enters Into Option Licensing Agreement With Stanford University 68
Stanford Health Care Acquires ValleyCare Health 69
Stanford Hospital Acquires CareCounsel Health Advocacy Specialist 70
Stanford University, Key Competitors 71
Stanford University, Key Employees 72
Stanford University, Subsidiaries 73
Why Buy From US?
What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story
We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.
While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.
With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.
Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.
If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.